MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma
Soft-tissue sarcoma (STS) is represented by a heterogeneous group of rare malignancies with various molecular oncogenesis. Therapies targeting DNA repair pathways in STS have achieved minimal progress, potentially due to the lack of molecular biomarker(s) beyond the histology subtype. In this report...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-06-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2021.666376/full |
| _version_ | 1819098495248760832 |
|---|---|
| author | Qi Liu Qiyuan Bao Yiqi Xu Yucheng Fu Zhijian Jin Jun Wang Weibin Zhang Weibin Zhang Yuhui Shen Yuhui Shen |
| author_facet | Qi Liu Qiyuan Bao Yiqi Xu Yucheng Fu Zhijian Jin Jun Wang Weibin Zhang Weibin Zhang Yuhui Shen Yuhui Shen |
| author_sort | Qi Liu |
| collection | DOAJ |
| description | Soft-tissue sarcoma (STS) is represented by a heterogeneous group of rare malignancies with various molecular oncogenesis. Therapies targeting DNA repair pathways in STS have achieved minimal progress, potentially due to the lack of molecular biomarker(s) beyond the histology subtype. In this report, we comprehensively analyzed the expression profiles of 100 liposarcomas (LPSs), the most common STS subtype, in comparison with 21 adipose tissues from multiple GEO datasets to identify the potential prognostic and therapeutic biomarker for LPS. Furthermore, we investigated TCGA database, our archived tumor samples, and patient-derived tumor cell cultures (PTCCs) as a validation. We identified a total of 69 common differentially expressed genes (DEGs) among public datasets, with mini-chromosome maintenance protein 4 (MCM4) identified as a novel biomarker correlated with patients’ clinical staging and survival outcome. MCM4-high expression LPS was characterized by MCM4 copy number increase, genomic instability, and BRCAness phenotype compared with the MCM4-low expression counterpart. In contrast, the mutational and the immune landscape were minimally different between the two groups. Interestingly, the association of MCM4-high expression with genomic instability and BRCAness were not only validated in LPS samples from our institution (n = 66) but also could be expanded to the pan-sarcoma cohort from TCGA database (n = 263). Surprisingly, based on four sarcoma cell lines and eight PTCCs (three LPS and five other sarcoma), we demonstrated that MCM4 overexpression tumors were therapeutically sensitive to PARP inhibitor (PARPi) and platinum chemotherapy, independent of the histology subtypes. Our study, for the first time, suggested that MCM4 might be a novel prognostic biomarker, associated with dysregulated DNA repair pathways and potential therapeutic vulnerability in STS. |
| first_indexed | 2024-12-22T00:31:53Z |
| format | Article |
| id | doaj.art-5f5aa6a4ce774f208cd2a0e77cc3e4b3 |
| institution | Directory Open Access Journal |
| issn | 2296-634X |
| language | English |
| last_indexed | 2024-12-22T00:31:53Z |
| publishDate | 2021-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj.art-5f5aa6a4ce774f208cd2a0e77cc3e4b32022-12-21T18:44:54ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2021-06-01910.3389/fcell.2021.666376666376MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue SarcomaQi Liu0Qiyuan Bao1Yiqi Xu2Yucheng Fu3Zhijian Jin4Jun Wang5Weibin Zhang6Weibin Zhang7Yuhui Shen8Yuhui Shen9Department of Orthopedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Orthopedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Orthopedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Orthopedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Orthopedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaShanghai Institute of Orthopedics and Traumatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Orthopedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaShanghai Institute of Orthopedics and Traumatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Orthopedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaShanghai Institute of Orthopedics and Traumatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSoft-tissue sarcoma (STS) is represented by a heterogeneous group of rare malignancies with various molecular oncogenesis. Therapies targeting DNA repair pathways in STS have achieved minimal progress, potentially due to the lack of molecular biomarker(s) beyond the histology subtype. In this report, we comprehensively analyzed the expression profiles of 100 liposarcomas (LPSs), the most common STS subtype, in comparison with 21 adipose tissues from multiple GEO datasets to identify the potential prognostic and therapeutic biomarker for LPS. Furthermore, we investigated TCGA database, our archived tumor samples, and patient-derived tumor cell cultures (PTCCs) as a validation. We identified a total of 69 common differentially expressed genes (DEGs) among public datasets, with mini-chromosome maintenance protein 4 (MCM4) identified as a novel biomarker correlated with patients’ clinical staging and survival outcome. MCM4-high expression LPS was characterized by MCM4 copy number increase, genomic instability, and BRCAness phenotype compared with the MCM4-low expression counterpart. In contrast, the mutational and the immune landscape were minimally different between the two groups. Interestingly, the association of MCM4-high expression with genomic instability and BRCAness were not only validated in LPS samples from our institution (n = 66) but also could be expanded to the pan-sarcoma cohort from TCGA database (n = 263). Surprisingly, based on four sarcoma cell lines and eight PTCCs (three LPS and five other sarcoma), we demonstrated that MCM4 overexpression tumors were therapeutically sensitive to PARP inhibitor (PARPi) and platinum chemotherapy, independent of the histology subtypes. Our study, for the first time, suggested that MCM4 might be a novel prognostic biomarker, associated with dysregulated DNA repair pathways and potential therapeutic vulnerability in STS.https://www.frontiersin.org/articles/10.3389/fcell.2021.666376/fullmini-chromosome maintenance protein 4 (MCM4)soft-tissue sarcomaliposarcomagenome instabilityBRCAness phenotype |
| spellingShingle | Qi Liu Qiyuan Bao Yiqi Xu Yucheng Fu Zhijian Jin Jun Wang Weibin Zhang Weibin Zhang Yuhui Shen Yuhui Shen MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma Frontiers in Cell and Developmental Biology mini-chromosome maintenance protein 4 (MCM4) soft-tissue sarcoma liposarcoma genome instability BRCAness phenotype |
| title | MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma |
| title_full | MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma |
| title_fullStr | MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma |
| title_full_unstemmed | MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma |
| title_short | MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma |
| title_sort | mcm4 is a novel biomarker associated with genomic instability brcaness phenotype and therapeutic potentials in soft tissue sarcoma |
| topic | mini-chromosome maintenance protein 4 (MCM4) soft-tissue sarcoma liposarcoma genome instability BRCAness phenotype |
| url | https://www.frontiersin.org/articles/10.3389/fcell.2021.666376/full |
| work_keys_str_mv | AT qiliu mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma AT qiyuanbao mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma AT yiqixu mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma AT yuchengfu mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma AT zhijianjin mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma AT junwang mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma AT weibinzhang mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma AT weibinzhang mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma AT yuhuishen mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma AT yuhuishen mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma |